{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-072356","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.504029+00:00","generated_at":"2026-05-23T22:41:43.292521+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Autolus Therapeutics VP Finance resigns; CFO Dolski appointed PAO","bullets":["Andrew Mercieca resigned as VP Finance & PAO on Feb 24, 2025, effective August 2025; not due to any disagreement.","CFO Rob Dolski appointed principal accounting officer effective April 3, 2025, in addition to his CFO role.","No additional compensation for Dolski for the added PAO duties; no family or transaction disclosures.","Mercieca's resignation follows a statutory three-month minimum notice period under UK law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-072356","json":"https://secwatch.observer/filing/0001193125-25-072356.json","markdown":"https://secwatch.observer/filing/0001193125-25-072356.md","text":"https://secwatch.observer/filing/0001193125-25-072356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/0001193125-25-072356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/d945856d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:41:43.292521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04577691f8","claim":"Rob Dolski was appointed as principal accounting officer at Autolus Therapeutics plc.","evidence_excerpt":"On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/0001193125-25-072356-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"11287df562","claim":"Andrew Mercieca resigned as Vice President of Finance and principal accounting officer at Autolus Therapeutics plc.","evidence_excerpt":"On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/0001193125-25-072356-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Vice President of Finance and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}